Successful Pregnancy after Treatment with Ulipristal Acetate for Uterine Fibroids
This case report presents a clinical pregnancy after ulipristal acetate (UA) to decrease uterine fibroid size. A 37-year-old patient, gravida 1, abortus 1, with uterine fibroids was treated with 5 mg of UA daily for 13 weeks starting eight months after a multiple laparotomic myomectomy. Fibroid shri...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Case Reports in Obstetrics and Gynecology |
| Online Access: | http://dx.doi.org/10.1155/2014/314587 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850235006212898816 |
|---|---|
| author | Javier Monleón Alicia Martínez-Varea Daniela Galliano Antonio Pellicer |
| author_facet | Javier Monleón Alicia Martínez-Varea Daniela Galliano Antonio Pellicer |
| author_sort | Javier Monleón |
| collection | DOAJ |
| description | This case report presents a clinical pregnancy after ulipristal acetate (UA) to decrease uterine fibroid size. A 37-year-old patient, gravida 1, abortus 1, with uterine fibroids was treated with 5 mg of UA daily for 13 weeks starting eight months after a multiple laparotomic myomectomy. Fibroid shrinkage and restoration of the morphology of endometrial cavity were evaluated in order to allow a subsequent pregnancy. A decrease of the uterine fibroids and a normal morphology of the endometrial cavity were noted by transvaginal ultrasound after treatment. An endometrial biopsy excluded histologic endometrial changes. Three months after the end of UA the patient reported amenorrhea for 5 weeks and a clinical pregnancy was confirmed with transvaginal ultrasound. She underwent a subsequent uneventful pregnancy. Thus, the spontaneous pregnancy after UA to reduce fibroid size may support the potential clinical utility of this selective progesterone receptor modulator in the management of women with pregnancy desire and uterine fibroids after a prior myomectomy. Patients who refuse a new surgical procedure and/or those who are going to undergo assisted reproductive techniques would benefit from UA. It effectively shrinks fibroids, avoids risks of a new surgical procedure, and allows an immediate attempt at conception after the end of treatment. |
| format | Article |
| id | doaj-art-0dc48751c8d142de8958c8e35df11513 |
| institution | OA Journals |
| issn | 2090-6684 2090-6692 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Obstetrics and Gynecology |
| spelling | doaj-art-0dc48751c8d142de8958c8e35df115132025-08-20T02:02:26ZengWileyCase Reports in Obstetrics and Gynecology2090-66842090-66922014-01-01201410.1155/2014/314587314587Successful Pregnancy after Treatment with Ulipristal Acetate for Uterine FibroidsJavier Monleón0Alicia Martínez-Varea1Daniela Galliano2Antonio Pellicer3Department of Obstetrics and Gynecology, La Fe University Hospital, Bulevar Sur s/n, 46026 Valencia, SpainDepartment of Obstetrics and Gynecology, La Fe University Hospital, Bulevar Sur s/n, 46026 Valencia, SpainInstituto Valenciano de Infertilidad (IVI), 08017 Barcelona, SpainDepartment of Obstetrics and Gynecology, La Fe University Hospital, Bulevar Sur s/n, 46026 Valencia, SpainThis case report presents a clinical pregnancy after ulipristal acetate (UA) to decrease uterine fibroid size. A 37-year-old patient, gravida 1, abortus 1, with uterine fibroids was treated with 5 mg of UA daily for 13 weeks starting eight months after a multiple laparotomic myomectomy. Fibroid shrinkage and restoration of the morphology of endometrial cavity were evaluated in order to allow a subsequent pregnancy. A decrease of the uterine fibroids and a normal morphology of the endometrial cavity were noted by transvaginal ultrasound after treatment. An endometrial biopsy excluded histologic endometrial changes. Three months after the end of UA the patient reported amenorrhea for 5 weeks and a clinical pregnancy was confirmed with transvaginal ultrasound. She underwent a subsequent uneventful pregnancy. Thus, the spontaneous pregnancy after UA to reduce fibroid size may support the potential clinical utility of this selective progesterone receptor modulator in the management of women with pregnancy desire and uterine fibroids after a prior myomectomy. Patients who refuse a new surgical procedure and/or those who are going to undergo assisted reproductive techniques would benefit from UA. It effectively shrinks fibroids, avoids risks of a new surgical procedure, and allows an immediate attempt at conception after the end of treatment.http://dx.doi.org/10.1155/2014/314587 |
| spellingShingle | Javier Monleón Alicia Martínez-Varea Daniela Galliano Antonio Pellicer Successful Pregnancy after Treatment with Ulipristal Acetate for Uterine Fibroids Case Reports in Obstetrics and Gynecology |
| title | Successful Pregnancy after Treatment with Ulipristal Acetate for Uterine Fibroids |
| title_full | Successful Pregnancy after Treatment with Ulipristal Acetate for Uterine Fibroids |
| title_fullStr | Successful Pregnancy after Treatment with Ulipristal Acetate for Uterine Fibroids |
| title_full_unstemmed | Successful Pregnancy after Treatment with Ulipristal Acetate for Uterine Fibroids |
| title_short | Successful Pregnancy after Treatment with Ulipristal Acetate for Uterine Fibroids |
| title_sort | successful pregnancy after treatment with ulipristal acetate for uterine fibroids |
| url | http://dx.doi.org/10.1155/2014/314587 |
| work_keys_str_mv | AT javiermonleon successfulpregnancyaftertreatmentwithulipristalacetateforuterinefibroids AT aliciamartinezvarea successfulpregnancyaftertreatmentwithulipristalacetateforuterinefibroids AT danielagalliano successfulpregnancyaftertreatmentwithulipristalacetateforuterinefibroids AT antoniopellicer successfulpregnancyaftertreatmentwithulipristalacetateforuterinefibroids |